Literature DB >> 6589436

Correlation of tumor growth inhibitory activity of macrophages exposed to adriamycin and adriamycin sensitivity of the target tumor cells.

R Giavazzi, C D Bucana, I R Hart.   

Abstract

Variant cell lines of the murine fibrosarcoma UV-2237, selected for doxorubicin [adriamycin (ADM)] resistance, were used to study the tumoricidal activity of macrophages that had been exposed to ADM. Free ADM (0.01-1 microgram/ml) was cytotoxic to the sensitive UV-2237M parent and to the partially sensitive UV-2237M-revertant cell lines, whereas the ADM-resistant UV-2237M ADMR line was unaffected by these levels of ADM. Macrophages harvested from the peritoneal cavities of mice given ip injections of 10 mg ADM/kg body weight 1 day or 4 days previously inhibited proliferation of the 3 cell lines, an effect that was directly correlated to the degree of ADM sensitivity of each cell line. Macrophages exposed in vitro to ADM (from 0.01 to 1 microgram/ml) inhibited the growth of, and eventually were cytolytic to, the parent and the revertant cell lines; these ADM-exposed macrophages did not affect the UV-2237M-ADMR cell line. The correlation between the antitumor effects of macrophages exposed to ADM and the ADM susceptibility of tumor cells suggests that ADM-exposed macrophages exert their effect by the release or transfer of the stored drug.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6589436     DOI: 10.1093/jnci/73.2.447

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  9 in total

1.  Cancer chemotherapeutics as immunomodulators.

Authors:  F Spreafico; A Vecchi; F Colotta; A Montovani
Journal:  Springer Semin Immunopathol       Date:  1985

Review 2.  Macrophages and cancer.

Authors:  P W Whitworth; C C Pak; J Esgro; E S Kleinerman; I J Fidler
Journal:  Cancer Metastasis Rev       Date:  1990-02       Impact factor: 9.264

Review 3.  Immune-based therapeutics for pediatric cancer.

Authors:  Christian M Capitini; Crystal L Mackall; Alan S Wayne
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

4.  Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid).

Authors:  E S Kleinerman; A K Raymond; C D Bucana; N Jaffe; M B Harris; I H Krakoff; R Benjamin; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

5.  A novel N-myristylated synthetic octapeptide inhibits protein kinase C activity and partially reverses murine fibrosarcoma cell resistance to adriamycin.

Authors:  C A O'Brian; N E Ward; R M Liskamp; D B de Bont; L E Earnest; J H van Boom; D Fan
Journal:  Invest New Drugs       Date:  1991-05       Impact factor: 3.850

6.  Effect of Adriamycin on liposomal muramyl tripeptide's ability to up-regulate monocyte cytokine expression.

Authors:  T Asano; W Fujimaki; A McWatters; T An; K Matsushima; E S Kleinerman
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

7.  Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice.

Authors:  H Shindo; T Ogura; T Masuno; S Hayashi; S Kishimoto
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

8.  Effect of intraperitoneal injection of mitomycin C adsorbed on activated carbon particles on induction of cytolytic peritoneal macrophages of mice.

Authors:  M Sakita; A Iwamoto; K Hata; A Hagiwara; T Takahashi
Journal:  Jpn J Cancer Res       Date:  1989-12

9.  Antitumor effect of liposome-entrapped adriamycin administered via the portal vein.

Authors:  T Ichino; T Yotsuyanagi; I Mizuno; Y Akamo; T Yamamoto; T Saito; S Kurahashi; N Tanimoto; J Yura
Journal:  Jpn J Cancer Res       Date:  1990-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.